Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.
Signed Informed Consent Form.
Age ≥ 18 years at the time of signing Informed Consent Form.
Ability to fully comply with the protocol, in the investigator's judgment.
Diagnosis of HCC confirmed by histology.
Presence of extrahepatic disease or macrovascular invasion.
Known fibrolamellar HCC, sarcomatoid HCC, mixed cholangiocarcinoma and HCC, or other rare variants of HCC.
History of hepatic encephalopathy if clinically significant within one year prior to screening.
CSPH in candidates for major resection (more than 3 segments).